DMSO stock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Therefore, NTCP inhibitors, such as cyclosporine A, ketoconazole, propranolol, furosemide, rifamycin, saquinavir, and ritonavir, should theoretically cause cholestasis by decreasing hepatocyte BA uptake. However, no relationship was found between NTCP inhibition and DIC risk, possibly because basolateral sodium-independent OATPs can partially compensate for bile salt uptake. Therefore, NTCP inhibition alone seems to be insufficient for causeing cholestasis. Indeed, the cholestatic effect of cyclosporine A relies on its inhibition of both NTCP and the compensatory OATP1B1. In addition to direct inhibition, drugs can also induce cholestasis by promoting downregulation and internalization of transporters. For example, cyclosporine A in rats was shown to induce BSEP internalization in addition to inhibition. Furthermore, human hepatocytes showed decreased expression of BSEP mRNA and protein following long-term exposure to metformin and tamoxifen, neither of which are direct BSEP inhibitors. Bile canaliculi dynamics refers to the contractile motion of bile canaliculi (ducts) required for bile flow. Cholestasis can result when drugs constrict or dilate bile canaliculi. Constrictors include chlorpromazine, nefazodone, troglitazone, perhexiline, metformin, cyclosporin A. These drugs activate the RhoA/Rho-kinase pathway, which inhibits myosin light chain phosphatase (MLCP), and in turn, increases myosin light chain phosphorylation by MLC kinase leading to constriction of bile canaliculi.
Richard A. Houghten is a heterocyclic organic chemist and founder of the journal Peptide Research, which was later merged with the International Journal of Peptide and Protein Research, to become the Journal of Peptide Research. His work mainly concerns peptide activity and pharmacology. He is the founder and president of the Torrey Pines Institute for Molecular Studies (TPIMS), a biomedical research institute. Houghten pioneered the "tea-bag" approach of producing peptides for pharmacological work. He is author of over five hundred scientific papers, 38 of which have been cited at least one hundred times. His h-index is over 60.
==== Urinary system ==== The urinary system is the part of the excretory system that removes waste in the form of urine, comprising the kidneys, ureters, bladder, and the urethra. Other purposes of the urinary system include the regulation of blood volume and blood pressure; the control of electrolyte and metabolite levels; and the regulation of blood pH. Each kidney consists of functional units called nephrons. Following filtration of blood and further processing, the ureters carry urine from the kidneys into the urinary bladder. During urination, the urethra carries urine out of the bladder through the penis or vulva. The female and male urinary system are very similar, differing only in the length of the urethra.
MDMA - Isomer Design MDMA - PsychonautWiki MDMA - Erowid MDMA - PiHKAL - Erowid MDMA - PiHKAL - Isomer Design A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for PTSD (MAPP2) "MDMA Facts and Statistics". National Institute on Drug Abuse. 15 June 2020.
=== Development === Development of the film was announced on 20 December 2008, although writer Alex Garland had begun working on the script in 2006. British studio DNA Films produced the film, and partnered with sales agency IM Global to sell the worldwide distribution rights. By May 2010, this partnership saw IM Global and its owner Reliance Big Pictures agree to co-finance the 3-D project with a $45 million production budget, and a schedule to begin filming in Johannesburg, South Africa in late 2010. Pete Travis was named as the film's director and Garland, Andrew Macdonald and Allon Reich would produce it. Duncan Jones had previously been offered the role of director. In a 2010 interview, Jones said that his vision for the film was unconventional—describing it as weird, dark, and funny—and it did not mesh well with Garland's script. In September 2010, it was reported that the film would be titled Dredd. Pre-production commenced on 23 August 2010 at Cape Town Film Studios in Cape Town, South Africa. During the 2010 San Diego Comic-Con in July, Urban confirmed that he had been offered the role of Judge Dredd, and on 18 August 2010, it was reported that Urban had the role. In September 2010, it was announced that Thirlby would play Dredd's telepathic rookie Cassandra Anderson. In the same month during the Toronto International Film Festival, the film attracted $30 million in worldwide pre-sales to distributors in 90% of theatrical markets. The sales included a $7 million deal with British distributor Entertainment Film Distributors.
Sources: en.wikipedia.org
=== Accelerated consumer adoption === The pandemic dramatically increased public awareness of diagnostic testing and normalized at-home health monitoring. Self-testing kits for COVID-19 familiarized millions of consumers with the concept of collecting samples at home, reducing barriers to adoption of other DTC testing services. The blood sample segment dominated the self-testing market with approximately 35.19% revenue share in 2024.
Some proteins then excise internal segments from their own peptide chains, splicing the free ends that border the gap; in such processes the inside "discarded" sections are called inteins. Other proteins must be split into multiple sections without splicing. Some polypeptide chains need to be cross-linked, and others must be attached to cofactors such as haem (heme) before they become functional.
However, there has been criticism where it favors the idea for lips, with the 2017 analytical study proposing that tyrannosaurids had large, flat scales on their snouts instead of lips, as modern crocodiles do. But crocodiles possess rather cracked keratinized skin, not flat scales; by observing the hummocky rugosity of tyrannosaurids, and comparing it to extant lizards, researchers have found that tyrannosaurids had squamose scales rather than a crocodillian-like skin. In 2023, Cullen and colleagues supported the idea that theropods like tyrannosaurids had lips based on anatomical patterns, such as those of the foramina on their face and jaws, more similar to those of modern squamates such as monitor lizards or marine iguanas than those of modern crocodilians like alligators. Comparison of the teeth of Daspletosaurus and American alligators shows that the enamel of tyrannosaurids had no significant wear and that the teeth of modern crocodilians were eroded on the labial side and were substantially worn. This suggests that it is likely that theropod teeth were kept wet by lips. On the basis of the relationship between hydration and wear resistance, the authors argued that it is unlikely that the teeth of theropods, including tyrannosaurids, would have remained unworn when exposed for a long time, because it would have been hard to maintain hydration.
== Mechanism == The protein obeys Michaelis-Menton kinetics and has an associated KM of 278 ± 49 μM. The GYDQL and YFPQA motifs on the C-terminal binds cystinosin to the lysosome. Mutations in the GYDQL motif cause a repositioning of cystinosin to being partially on the plasma membrane and partially on the lysosome. Mutations in both GYDQL and YFPQA motifs cause cystinosin to position itself to the plasma membrane instead of lysosomes An increase in acidity in the lumen of the lysosome initiates the reaction of CySS and H+ being transported into the cytosol.
=== Economics === Trastuzumab costs about US$70,000 for a full course of treatment. Australia has negotiated a lower price of A$50,000 per course of treatment. Since October 2006, trastuzumab has been made available for Australian women and men with early-stage breast cancer via the Pharmaceutical Benefits Scheme. This is estimated to cost the country over A$470 million for 4–5 years supply of the drug. Roche has agreed with Emcure in India to make an affordable version of this cancer drug available to the Indian market. Roche has changed the brand name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately RS75,000 INR (US$ 870) in the Indian market. On 16 September 2014, Genentech notified hospitals in the United States that, as of October, trastuzumab could only be purchased through their selected specialty drugs distributors not through the usual general line wholesalers. By being forced to purchase through specialty pharmacies, hospitals lost rebates from the big wholesalers and the ability to negotiate cost-minus discounts with their wholesalers.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.